Видео ютуба по тегу Event: Iwcll 2025

IWCLL Conference - ICE Cracow 2025
IWCLL Conference - ICE Cracow 2025
Highlights from a Young Investigator Meeting session at iwCLL 2025
Highlights from a Young Investigator Meeting session at iwCLL 2025
Considering long-term treatment goals when selecting frontline therapy for patients with CLL
Considering long-term treatment goals when selecting frontline therapy for patients with CLL
Watch Drs. Ghia, Davids, & Scarfò discuss #CLL updates from #iWCLL
Watch Drs. Ghia, Davids, & Scarfò discuss #CLL updates from #iWCLL
A tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
A tandem CD19/ROR1 CAR-NK to overcome apoptotic resistance in CLL
Ongoing projects to improve the outcomes of patients with CLL in resource-limited settings
Ongoing projects to improve the outcomes of patients with CLL in resource-limited settings
The emerging promise of targeted protein degraders in CLL and other hematological malignancies
The emerging promise of targeted protein degraders in CLL and other hematological malignancies
MAVRiC trial: mutation-guided time-limited AV after frontline cBTKi + ven in patients with CLL/SLL
MAVRiC trial: mutation-guided time-limited AV after frontline cBTKi + ven in patients with CLL/SLL
Outcomes with ven-based therapy in 1L or 2L high-risk CLL/SLL: a real-world international study
Outcomes with ven-based therapy in 1L or 2L high-risk CLL/SLL: a real-world international study
The ongoing rapid pace of advancement in CLL: practice-changing developments and promising therapies
The ongoing rapid pace of advancement in CLL: practice-changing developments and promising therapies
Safety and efficacy of var-cel (ARI-0001) in patients with R/R CLL and Richter's transformation
Safety and efficacy of var-cel (ARI-0001) in patients with R/R CLL and Richter's transformation
The potential role of BCL2 inhibitors in the CLL treatment landscape
The potential role of BCL2 inhibitors in the CLL treatment landscape
The potential role of therapies targeting surface antigens in the CLL treatment landscape
The potential role of therapies targeting surface antigens in the CLL treatment landscape
MRD-guided ibrutinib-venetoclax versus ibrutinib or FCR for previously untreated CLL: FLAIR trial
MRD-guided ibrutinib-venetoclax versus ibrutinib or FCR for previously untreated CLL: FLAIR trial
The potential of bispecific antibodies in CLL
The potential of bispecific antibodies in CLL
Updates to the CLL treatment guidelines in the UK: continuous and fixed-duration therapy options
Updates to the CLL treatment guidelines in the UK: continuous and fixed-duration therapy options
Where will the field of CLL move in the coming years?
Where will the field of CLL move in the coming years?
The development and implementation of a novel flow cytometry CD19-agnostic MRD assay in CLL
The development and implementation of a novel flow cytometry CD19-agnostic MRD assay in CLL
Improving the targeting of surface antigens in CLL: moving beyond monoclonal antibodies
Improving the targeting of surface antigens in CLL: moving beyond monoclonal antibodies